Ratings by Raymond James (Martin Auster)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/24/2026 | Shattuck Labs | STTK | New Coverage | Strong Buy (N/A) |
7.53 (6.87) |
-8.76% | Details | |
| 8/3/2026 | Alnylam Pharmaceuticals | ALNY | Upgrade | Strong Buy (Outperform) |
205.52 (246.11) |
19.75% | Details | |
| 6/29/2026 | Evommune Inc | EVMN | Downgrade | Outperform (Strong Buy) |
25.18 (12.48) |
-50.44% | Details | |
| 6/8/2026 | Septerna Inc | SEPN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/8/2026 | iBio, Inc. | IBIO | New Coverage | Outperform (N/A) |
1.82 (1.26) |
-30.77% | Details | |
| 6/1/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/26/2026 | BridgeBio Pharma | BBIO | Downgrade | Market Perform (Outperform) |
70.28 (76.57) |
8.95% | Details | |
| 5/26/2026 | Tectonic Therapeutics Inc. | TECX | Upgrade | Strong Buy (Outperform) |
28.52 (31.22) |
9.47% | Details | |
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Equillium | EQ | New Coverage | Strong Buy (N/A) |
1.80 (2.21) |
22.78% | Details | |
| 4/13/2026 | Spyre | SYRE | New Coverage | Strong Buy (N/A) |
51.29 (88.50) |
72.55% | Details | |
| 3/31/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Maze Therapeutics | MAZE | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/10/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/26/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/19/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Strong Buy (N/A) |
8.16 (6.34) |
-22.3% | Details | |
| 2/12/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Evommune Inc | EVMN | New Coverage | Strong Buy (N/A) |
16.08 (25.18) |
56.59% | Details | |
| 12/19/2025 | Septerna Inc | SEPN | New Coverage | Strong Buy (N/A) |
27.54 (37.68) |
36.82% | Details | |
| 12/12/2025 | Phathom Pharmaceuticals | PHAT | New Coverage | Strong Buy (N/A) |
14.55 (9.39) |
-35.46% | Details | |
| 12/8/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/13/2025 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
32.56 (26.53) |
-18.52% | Details | |
| 10/31/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/30/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Ascendis Pharma | ASND | New Coverage | Strong Buy (N/A) |
207.12 (260.25) |
25.65% | Details | |
| 8/7/2025 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/6/2025 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
324.79 (205.52) |
-36.72% | Details | |
| 7/30/2025 | Cytokinetics | CYTK | Downgrade | Market Perform (Outperform) |
36.63 (71.40) |
94.92% | Details | |
| 7/30/2025 | Edgewise Therapeutics | EWTX | New Coverage | Strong Buy (N/A) |
14.26 (42.25) |
196.28% | Details | |
| 7/30/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
46.23 (70.28) |
52.02% | Details | |
| 7/29/2025 | Scholar Rock | SRRK | New Coverage | Strong Buy (N/A) |
37.09 (55.89) |
50.69% | Details |
